NCT07853612Active, not recruitingPhase 4
Effect of Two Weeks of Low-Dose Apixaban on Platelet Reactivity in Patients With Stable Coronary Artery Disease on Dual Antiplatelet Therapy (Aspirin and Clopidogrel)
The Effects of Apixaban on Platelet Function Profiles in Patients With Stable Coronary Artery Disease: The ACER Pilot Study
Source: ClinicalTrials.gov · Last updated 2 Oct 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn whether a low dose of apixaban, a blood-thinning medicine, changes how active the platelets are in adults with stable coronary artery disease who are already taking aspirin and clopidogrel. Platelets are small blood cells that help form clots. Aspirin and clopidogrel are used to keep platelets from clumping and to lower the risk of heart attack and stroke. In some people, however, platelets stay very active even while taking these medicines, which raises the risk of future heart problems. Apixaban works on a different part of the clotting process, and researchers want to find out whether it lowers platelet activity further. The main questions it aims to answer are: Does taking low-dose apixaban for 14 days lower platelet activity, as measured by the VerifyNow P2Y12 test (reported as P2Y12 reaction units, or PRU)? Does low-dose apixaban change how platelets respond to aspirin, as measured by the VerifyNow aspirin test (reported as aspirin reaction units, or ARU)? Is 14 days of low-dose apixaban, added to aspirin and clopidogrel, safe and well tolerated? There is no separate comparison group. Researchers will compare each participant's platelet test results before starting apixaban with that same participant's results after 14 days of apixaban. Participants will: Have a screening interview and a review of their medical history and current medicines Give a small blood sample (about 5 mL) for platelet function testing before starting apixaban Take apixaban 2.5 mg by mouth twice a day for 14 days, while continuing their usual aspirin and clopidogrel Return on Day 14 to give a second blood sample for platelet function testing and safety blood tests Receive a phone call from a study doctor at Day 30 to check for side effects or other health problems Participants will receive a copy of their platelet test results. This is a small pilot study of about 16 participants at one site in Trinidad and Tobago.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 16 (estimated)
- First submitted
- 26 Sept 2026
- Start date
- 3 Sept 2026
- Primary completion date
- 1 Oct 2027
- Lead sponsor
- The University of The West Indies
- Diseases
- Coronary artery disease
- NCT number
- NCT07853612
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 16
- From 3 Sept 2026 to the primary completion date, 1 Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- within 30 days of coronary artery bypass graft surgery,
- treatment with fibrin-specific fibrinolytic therapy \<24 h or non-fibrin-specific fibrinolytic therapy \<48 h,
Other illness
- presence of active internal bleeding or history of bleeding diathesis or clinical findings associated with an increased risk of bleeding,
- history of ischemic or hemorrhagic stroke, transient ischemic attack, intracranial neoplasm, arteriovenous malformation, or aneurysm,
- history of clinical and/or hemodynamic instability,
- known allergy or contraindication to apixaban,
Lab values
- hemoglobin \<10 g/dL,
- platelet count \<100000/μL,
- creatinine \>2 mg/dL,
Age
- age \>75 years,
Other
- within 1 month of placement of a bare metal stent,
- planned coronary revascularization,
- use of an oral anticoagulation agent or an international normalized ratio \>1.5,
- body weight \<60 kg,
- hepatic enzymes \>2.5 times the upper limit of normal,
- pregnancy and/or lactation,
- use of any other antiplatelet, anticoagulant, or antithrombotic agent,
- The inability to read or understand English.
Who the study is looking for
- between 18 and 74 years of age,
- have stable coronary artery disease, already on DAPT with aspirin and clopidogrel for at least 6 months,
- not on any physician-prescribed medications or complementary/alternative therapies.
Age in the registry: 18 years to 74 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Trinidad Institute of Medical Technology Coordinator of this site? Confirm its status | Saint Augustine | Trinidad and Tobago | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.